PreludeDx™ Announces Publication of Residual Risk after Radiation Therapy Data in the International Journal of Radiation Oncology•Biology•Physics

DCISionRT® is the first and only test for identification DCIS patients with an unexpectedly high residual risk after surgery and radiation

LAGUNA HILLS, California., September 20, 2022 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, today announced the release of clinical trial data in the International Journal of Radiation Oncology· biology· physics (“Red Diary”). The study showed that the DCISionRT® Residual Risk Subtype (RRt) identified patients with ductal carcinoma in situ (DCIS) who were at a much higher risk of recurrence after breast-conserving surgery (BCS) and radiation therapy (RT). The risk profile of these patients may justify intensification or alternative therapy considerations.

This study, titled “A novel biosignature identifies patients with DCIS at high risk of local recurrence after breast-conserving surgery and radiation therapy,” evaluated the 10-year risk of recurrence in 926 women diagnosed with DCIS and treated with BCS with or without RT. Patients in the RRt group had a 42% risk of recurrence after BCS and a significantly increased recurrence rate of 14.7% after BCS and RT.

“DCISionRT can help identify those women who might benefit from intensified or alternative therapy because they have an unexpectedly high risk of recurrence after standard treatment for DCIS,” said Frank Vinini, MD, radiation oncologist at GenesisCare, member of NRG Oncology and co-first author of the study. “This study demonstrates new utility and evidence to provide DCIS patients and their physicians with unique and valuable information beyond clinical and pathological characteristics to make treatment decisions based on a woman’s personal tumor biology.”

“Knowing whether a patient will experience minimal or significant benefit from radiation therapy, or whether she may need more intensive treatment, helps me and my colleagues provide truly personalized treatment to our DCIS patients,” he said Julie A MargenthalerMD, FACS, Professor of Surgery, Washington University School of Medicine and co-author of the study. “DCISionRT is an extremely valuable test for surgical and adjuvant (postoperative) treatment planning.”

“We are grateful for the multinational collaboration culminating in results being published in ASTRO’s official scientific journal,” said Dan Forche, President and CEO of PreludeDx. “The Residual Risk Subtype is an important advancement for patients and physicians that reinforces our commitment to contribute to optimal DCIS patient management with our proprietary DecisionTree^TM Risk profile and treatment outcomes.”

About DCISionRT for chest DCIS

DCISionRT is the only Risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts the benefit of radiation therapy. Patients with DCIS have cancer cells lining the breast milk ducts, but they have not spread to the surrounding breast tissue. In the United States, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT developed by PreludeDx on technology licensed from the University of California, San Francisco, and builds on research that began with funding from the National Cancer Institute, allows physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based scores to assess a woman’s individual tumor biology along with other pathological risk factors to provide a personalized risk of recurrence. The test provides a decision value^TM which identifies a woman’s risk as low or high. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathological factors, using a non-linear algorithm to account for multiple interactions between individual factors and better interpret complex biological information. DCISionRT’s intelligent reporting provides a woman’s risk of recurrence after breast-conserving surgery alone and with added radiation therapy. This new information, in turn, can help patients and their doctors make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Established in 2009 with licensed technology from University of California, San FranciscoPreludeDx has focused on developing precision breast cancer instruments that will influence a patient’s treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden on the healthcare system. Know Your Risk™ before making a treatment decision. PreludeDx is a portfolio company of Fjord Ventures.

For more information on how PreludeDx is making a difference to patients, visit the company’s website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, DecisionTree, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in The United States and abroad.

SOURCE PreludeDx